Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843023 · ClinicalTrials.gov registry record · Phase 4
Extended Release Naltrexone for Opioid-Dependent Youth
A Phase 4 study, sponsored by Friends Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 288
- Enrollment target
NCT01843023: Completed Phase 4 study, sponsored by Friends Research Institute.
NCT01843023 is a Phase 4 study that has completed, run by Friends Research Institute. The registered enrollment target is 288 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01843023, a Phase 4 study, has completed, sponsored by Friends Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 288 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
Primary Outcome
To determine the relative effectiveness of XR-NTX compared to TAU for opioid-dependent youth in terms of opioid use at 6-months post-treatment entry.
Interventions
- DRUG Buprenorphine
- BEHAVIORAL Psychosocial Treatment
- DRUG Extended Release Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2013-06 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
What the finished NCT01843023 record still lists
NCT01843023 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT01843023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01843023 about?
NCT01843023 is a clinical study titled "Extended Release Naltrexone for Opioid-Dependent Youth". The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
What is the current status of trial NCT01843023?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 288 participants. The study started on 2013-06. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01843023?
The interventions under investigation include: Buprenorphine (DRUG), Psychosocial Treatment (BEHAVIORAL), Extended Release Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01843023?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01843023's enrollment target sits among peer trials
288 298th of 2000 higher than 1,700 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia